Systematic Analysis of the Prognostic Value and Immunological Function of LTBR in Cancer
01-23-2024“[...] we identified LTBR as a potential target for cancer immunotherapy and a marker of immune infiltration and poor prognosis.”
Listen to an audio version of this press release
BUFFALO, NY- January 23, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “Systematic analysis of the prognostic value and immunological function of LTBR in human cancer.”
Lymphotoxin beta receptor (LTBR) is a positive T cell proliferation regulator gene. It is closely associated with the tumor immune microenvironment. However, its role in cancer and immunotherapy is unclear.
In this new study, researchers Yinteng Wu, Shijian Zhao, Wenliang Guo, Ying Liu, Marìa Del Mar Requena Mullor, Raquel Alarcòn Rodrìguez, and Ruqiong Wei from The First Affiliated Hospital of Guangxi Medical University, The Eighth Affiliated Hospital of Guangxi Medical University and University of Almerìa analyzed the expression level and prognostic value of LTBR in clinical stages, immune subtypes, and molecular subtypes. The correlation between LTBR and immune regulatory genes, immune checkpoint genes, and RNA modification genes was then analyzed. Correlations between LTBR and immune cells, scores, cancer-related functional status, tumor stemness index, mismatch repair (MMR) genes, and DNA methyltransferase were also analyzed.
In addition, the team analyzed the role of LTBR in DNA methylation, mutational status, tumor mutation burden (TMB), and microsatellite instability (MSI). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were used to explore the role of LTBR in pan-cancer. Finally, the drugs associated with LTBR were analyzed.
“In this work, we looked into the expression of LTBR at multiple levels.”
The expression of LTBR was confirmed using quantitative real-time PCR and Western blot. LTBR is significantly overexpressed in most cancers and is associated with low patient survival. In addition, LTBR expression was strongly correlated with immune cells, score, cancer-related functional status, tumor stemness index, MMR genes, DNA methyltransferase, DNA methylation, mutational status, TMB, and MSI. Enrichment analysis revealed that LTBR was associated with apoptosis, necroptosis, and immune-related pathways. Finally, multiple drugs targeting LTBR were identified. LTBR is overexpressed in several tumors and is associated with a poor prognosis. It is related to immune-related genes and immune cell infiltration.
“Notably, we identified LTBR as a potential target for cancer immunotherapy and a marker of immune infiltration and poor prognosis. This study offers new possibilities for the diagnosis and treatment of cancer patients, instilling hope for improved outcomes.”
Read the full paper: DOI: https://doi.org/10.18632/aging.205356
Corresponding Author: Ruqiong Wei
Corresponding Email: ruqiongwei@sr.gxmu.edu.cn
Keywords: lymphotoxin beta receptor (LTBR), pan-cancer, immune microenvironment, T cell, drug sensitivity
Click here to sign up for free Altmetric alerts about this article.
About Aging-US:
Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.
Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Please visit our website at www.Aging-US.com and connect with us:
- X
- YouTube
- Spotify, Apple, SoundCloud, and available wherever you listen to podcasts
For media inquiries, please contact media@impactjournals.com.